In the Democratic Republic of Congo's Ebola outbreak, researchers have started a study of two experimental treatments in early July. The virus, Bundibugyo, has no specific treatments or vaccines. Over 1,400 people have been diagnosed and 438 have died.
A US missionary, Peter Stafford, was evacuated from the DRC to Germany for experimental Ebola treatment (MBP-134). Doctors highlight the inequity in global healthcare access, contrasting advanced treatments in Europe with limited resources in Africa, exacerbated by US aid cuts.
Life Biosciences has administered its experimental treatment ER-100, targeting age-related vision loss diseases like glaucoma and NAION, to the first participant in a Phase 1 clinical trial. The treatment aims to restore cellular gene expression patterns to a younger state. The primary focus of this early-stage trial is to assess the safety and tolerability of ER-100 in humans.
An experimental treatment using tocilizumab is showing effectiveness against the Andes hantavirus strain in Argentina's Patagonia region. Local doctor Fernando Tortosa developed the treatment, which aims to curb the exaggerated inflammatory response that makes the virus lethal. Nazareno Eggers, a survivor, credits the treatment and a healthy lifestyle for his recovery.
Alzheimer’s Research UK says patients at risk of being left behind as lack of formal or accurate diagnoses closes door to trialsPeople with Alzheimer’s disease are missing out on experimental treatments because they are not diagnosed early or accurately enough to be enrolled in clinical trials, a UK charity has said.Trials of Alzheimer’s drugs reached a record high this year, according to data published on Tuesday, but Alzheimer’s Research UK said too few UK patients were taking part because their diagnoses were delayed or were not specific enough. Continue reading...
The Food and Drug Administration said on Friday it will offer ultra-fast review to three psychedelic drugs being developed to treat mental health conditions, including depression, the latest indication of the Trump administration’s commitment to the experimental treatment approach. President Donald Trump signed an executive order last weekend directing the FDA and other federal agencies to speed access and loosen restrictions on psychedelics, a class of hallucinogenic drugs which remain illegal...
